Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 721 to 735 of 1561 results for do not do recommendations

  1. Practitioners and providers' awareness of risk in black, Asian and other minority ethnic groups: Are clinicians, practitioners and weight management service providers aware that black, Asian and other minority ethnic groups are at the same risk of type 2 diabetes and mortality at a lower BMI compared with the white population. If so, do they intervene at lower BMI and waist-to-height ratio thresholds?

    Recommendation ID CG189/11 Question Practitioners and providers' awareness of risk in black, Asian and other minority ethnic groups: Are

    Research recommendation
    Published
    30 September 2022

  2. How effective and cost effective are different types of intervention to prevent a range of cold-related illnesses and death? How do these vary with groups in different circumstances?

    Recommendation ID NG6/3 Question How effective and cost effective are different types of intervention to prevent a range of cold-related

    Research recommendation
    Published
    9 June 2015

  3. Individual circumstances and the risk of dependence: Do individual circumstances such as social distress, low income or limited access to alternative sources of support lead to an increased risk of problems associated with dependence on prescribed medicines?

    Recommendation ID NG215/04 Question Individual circumstances and the risk of dependence: Do individual circumstances such...

    Research recommendation
    Published
    11 May 2022

  4. System-level factors and the risk of dependence: Do system-level factors, such as training received by prescribers alter the risk of developing problems associated with dependence on prescribed medicines?

    Recommendation ID NG215/06 Question System-level factors and the risk of dependence: Do system-level factors, such as...

    Research recommendation
    Published
    11 May 2022

  5. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 November 2019
    View recommendations

    Sections for TA612

  6. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA805

  7. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

    Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    17 February 2021
    View recommendations

    Sections for TA673

  8. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

    Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA374

  9. Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

    Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding in adults.

    Technology appraisal guidance
    Published
    28 April 2004
    View recommendations

    Sections for TA78

  10. Reducing demands on health and social care services:- Do preventive oral health interventions in residential and nursing care homes reduce demands on other health and social care services?

    Recommendation ID NG48/5 Question Reducing demands on health and social care services:- Do preventive oral health...

    Research recommendation
    Published
    24 August 2016

  11. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    14 February 2023
    View quality statements

    Sections for QS22

  12. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

    Technology appraisal guidance
    Last updated
    10 August 2017
    View recommendations

    Sections for TA190

  13. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

    Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    25 January 2017
    View recommendations

    Sections for TA430

  14. What interventions are effective to support medicines adherence for people with complex psychosis in supported accommodation?

    Recommendation ID NG181/9 Question What interventions are effective to support medicines adherence for people with complex psychosis in

    Research recommendation
    Published
    26 October 2020

  15. Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

    Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults

    Technology appraisal guidance
    Published
    28 November 2012
    View recommendations

    Sections for TA266